Clinical Trial Update: A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists [Phase 3]

View source ↗

Summary

Phase 3 safety study of Xolair (omalizumab) in adults with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamines, H2 blockers, and/or le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Idiopathic Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2013-11-26